SINGAPORE (April 11): CIMB is maintaining its “add” recommendation on Tianjin Zhongxin Pharmaceutical which is riding on demand for drugs by China’s ageing population.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $4.99/month*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply